Final answer:
Among the antidepressants listed, Bupropion is the least likely to further prolong the QTC interval in a patient with existing QTC prolongation, making it a safer option compared to Citalopram, Escitalopram, Amitriptyline, and Olanzapine.
Step-by-step explanation:
A 65-year-old man with a history of hypertension, diabetes, and coronary heart disease is admitted for coronary artery bypass grafting and is found to be depressed post-operatively. Psychiatry evaluation reveals a prolonged QTC interval (greater than 500 ms), delaying the initiation of antidepressant therapy due to potential risks of further QTC prolongation. At a follow-up appointment, the patient remains significantly depressed, and a diagnosis of major depressive disorder (MDD) is confirmed. When selecting an antidepressant less likely to prolong the QTC interval, Bupropion is the medication of choice.
Bupropion is known to have a negligible effect on the QTC interval when compared to other antidepressants, making it safer for patients with pre-existing QTC prolongation. In contrast, Citalopram and Escitalopram are selective serotonin reuptake inhibitors (SSRIs) known for their potential to prolong the QTC interval. Amitriptyline, a tricyclic antidepressant, and Olanzapine, an antipsychotic, also have a higher risk of causing QTC prolongation. Therefore, among the options provided, Bupropion presents the least risk of further QTC interval prolongation.